Clinical Trials Directory

Trials / Unknown

UnknownNCT00274859

Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer

Multicenter Phase II Study Evaluating Gemcitabine and Oxaliplatin in the Treatment of Patients Suffering From Metastatic Breast Cancer Who Are Not Candidates For Treatment With Antracyclines and Taxanes

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
45 (estimated)
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with oxaliplatin works in treating patients with metastatic cancer who cannot receive anthracycline or taxane therapy.

Detailed description

OBJECTIVES: Primary * Determine the objective response rate in patients with metastatic cancer not amenable to anthracycline or taxane therapy treated with gemcitabine hydrochloride and oxaliplatin. Secondary * Determine the clinical benefit and tolerability of this regimen in these patients. * Determine the progression-free and overall survival of patients treated with this regimen. OUTLINE: This is an open-label, multicenter study. Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
DRUGgemcitabine hydrochloride
DRUGoxaliplatin

Timeline

Start date
2005-08-01
First posted
2006-01-11
Last updated
2008-07-24

Locations

14 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00274859. Inclusion in this directory is not an endorsement.